{"url_path":"/sec/otlk/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-060305-index.html","accession_number":"0001104659-26-060305","cik":"0001649989","ticker":"OTLK","issuer_name":"Outlook Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1649989/0001104659-26-060305-index.html","primary_entity_key":"0001649989","primary_entity_name":"Outlook Therapeutics, Inc."},"word_count":479,"has_tables":true,"body_markdown":"**Item 2.02 Results of Operations and Financial Condition.**\n\n \n\nOn May 13, 2026,\nthe Company announced that, as of March 31, 2026, it had approximately $7.7 million of cash and cash equivalents, which\ndoes not include $4.5 million of net proceeds from a registered direct equity offering completed in April 2026. This amount is unaudited\nand preliminary, is subject to normal quarterly closing processes and accounting review, and does not present all information necessary\nfor an understanding of the Company’s financial condition as of March 31, 2026. Actual results for the three months ended March 31,\n2026 will not be finalized until a later date and may differ materially from the above estimates**.**\n\n \n\n \n\n \n\n \n\n*The information contained in this Item 2.02 shall not be deemed\nfiled for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise\nsubject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities\nAct”), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act,\nregardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such\nfiling.*\n\n \n\n**Forward-Looking Statements**\n\n \n\nThis Current Report on Form 8-K contains forward-looking statements\nwithin the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the Company’s preliminary\ncash and cash equivalents as of March 31, 2026. These forward-looking statements are based on management’s current expectations,\nbeliefs, and assumptions, and they involve substantial risks and uncertainties and may be based on inaccurate assumptions that could cause\nactual results to differ materially from those expressed or implied in the forward-looking statements. The preliminary cash and cash equivalents\nas of March 31, 2026 included in this Current Report on Form 8-K represent the most current information available to management.\nGiven the nature of the preliminary financial results, the Company cannot assure that any outcome expressed in these forward-looking statements\nwill be realized in whole or in part. While the Company believes that its assumptions are reasonable, it is very difficult to predict\nthe impact of known factors, and it is impossible to anticipate all factors that could affect actual results. These forward-looking statements\nare subject to risks and uncertainties that could cause results and events to differ significantly from those expressed or implied by\nthe forward-looking statements, including the risks discussed under the heading “Risk Factors” in the Company’s Annual\nReport on Form 10-K for the year ended September 30, 2025 and subsequent filings by the Company. Such forward-looking statements\nare made only as of the date of this Current Report on Form 8-K. Except as required by law, the Company assumes no obligation to\nupdate any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available."}